The pandemic caused by the novel coronavirus has shut down countries around the world. One of society’s biggest hopes is that treatments or even vaccines can be developed.

Join STAT for a three-part digital event series covering the race for new medicines that will impact Covid-19. The audience will be joined by executives from companies leading the way in developing treatments, who will come prepared to answer tough questions. They’ll discuss current findings, clinical trials, and efforts to expedite approvals as we face this global pandemic.

This series will take place on Zoom, an interactive platform where attendees will be able to not only see the discussions live, but also participate by asking questions during the event. Access to the event is free. Access to the Zoom platform is limited to the first 1,000 attendees; any additional attendees will be able to watch the conversation in real-time via a live stream on STAT’s website.

Part 2: Antiviral treatments. What are the odds? April 22, 2020 at 1PM EST

• Sponsor Introduction: Richard Moscicki, M.D., chief medical officer and executive vice president of Science and Regulatory Advocacy, PhRMA
• Diana Brainard, senior vice president, HIV and Emerging Viral Infections at Gilead Sciences, Inc.
• Matt Herper, senior writer, medicine, and editorial director of events, STAT